Physician profile
Malcolm R Fraser
NPI 1861486177
$358,713.47
in general payments reported to CMS, 2019-2025
12 companies · $49K in 2025
The $49K reported for 2025 was more than what 99% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $17K · 2021: $26K · 2022: $47K · 2023: $73K · 2024: $64K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Consulting Fee: $38K · Travel and Lodging: $37K · Food and Beverage: $6,618 · Education: $16.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,827.16 |
| Consulting Fee | $37,584.58 |
| Travel and Lodging | $37,407.36 |
| Food and Beverage | $6,618.13 |
| Education | $16.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $163,422.01 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $106,529.26 | 2022-2025 | Ingrezza |
| Lilly USA, LLC | $20,769.52 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $19,256.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $15,259.40 | 2019 | |
| Allergan, INC. | $10,408.19 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $6,474.06 | 2023 | Gemtesa |
| Urovant Sciences INC | $6,264.48 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $4,360.92 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $3,404.46 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,400.00 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $164.79 | 2019-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.